Literature DB >> 3464690

The human invariant chain is the core protein of the human class II-associated proteoglycan.

K S Giacoletto, A J Sant, C Bono, J Gorka, D M O'Sullivan, V Quaranta, B D Schwartz.   

Abstract

The human class II-associated chondroitin sulfate proteoglycan (CSPG) was analyzed biochemically and immunologically to determine a possible relationship with the human invariant chain (gamma 1) and its related components. The CSPG was purified by a three-step procedure involving associative ion-exchange chromatography, immunoprecipitation, and dissociative ion-exchange chromatography. Treatment of the CSPG with chondroitinase revealed core proteins of Mr approximately 46,000, 38,000, and 28,000, with the 38,000 species most highly represented. Tryptic peptide analysis revealed identity of the peptides of the 38,000 Mr core protein and gamma 1, and of the 28,000 Mr species and p25. The CSPG and its core proteins were shown to react directly with the mouse anti-human invariant chain monoclonal antibody VIC-Y1 and a rabbit antiserum produced against a synthetic peptide corresponding to the C-terminal end of invariant chain. These results demonstrate that the invariant chain is the core protein of the class II-associated CSPG. In addition, virtually all the CSPG was shown to be present on the cell surface.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3464690      PMCID: PMC2188463          DOI: 10.1084/jem.164.5.1422

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  24 in total

1.  High resolution two-dimensional electrophoresis of proteins.

Authors:  P H O'Farrell
Journal:  J Biol Chem       Date:  1975-05-25       Impact factor: 5.157

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  cDNA clone for the human invariant gamma chain of class II histocompatibility antigens and its implications for the protein structure.

Authors:  L Claesson; D Larhammar; L Rask; P A Peterson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-12       Impact factor: 11.205

4.  Biosynthesis and maturation of HLA-DR antigens in vivo.

Authors:  M J Owen; A M Kissonerghis; H F Lodish; M J Crumpton
Journal:  J Biol Chem       Date:  1981-09-10       Impact factor: 5.157

5.  Cell-surface heparan sulfate. Mechanisms of proteoglycan-cell association.

Authors:  L Kjellén; A Oldberg; M Höök
Journal:  J Biol Chem       Date:  1980-11-10       Impact factor: 5.157

6.  Identification of a sulfate-bearing molecule associated with HLA class II antigens.

Authors:  A J Sant; S E Cullen; B D Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

7.  Monensin prevents terminal glycosylation of the N- and O-linked oligosaccharides of the HLA-DR-associated invariant chain and inhibits its dissociation from the alpha-beta chain complex.

Authors:  C E Machamer; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

8.  Analysis of the biosynthesis of HLA-DR glycoproteins in human malignant melanoma cell lines.

Authors:  K O Lloyd; J Ng; W G Dippold
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

9.  Pinocytosis in fibroblasts. Quantitative studies in vitro.

Authors:  R M Steinman; J M Silver; Z A Cohn
Journal:  J Cell Biol       Date:  1974-12       Impact factor: 10.539

10.  Demonstration of structural polymorphism among HLA-DR light chains by two-dimensional gel electrophoresis.

Authors:  D A Shackelford; J L Strominger
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

View more
  10 in total

1.  The invariant chain forms complexes with class II major histocompatibility complex molecules and antigenic peptides "in vivo".

Authors:  M Viguier; K Dornmair; B R Clark; H M McConnell
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

2.  Four Ia invariant chain forms derive from a single gene by alternate splicing and alternate initiation of transcription/translation.

Authors:  D M O'Sullivan; D Noonan; V Quaranta
Journal:  J Exp Med       Date:  1987-08-01       Impact factor: 14.307

3.  Role for intracellular proteases in the processing and transport of class II HLA antigens.

Authors:  J S Blum; P Cresswell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

4.  Ultrastructural localization and internalization of proteoglycan epitopes in a human non-Hodgkin (B) lymphoma.

Authors:  J Timár; I Kovalszky; A Bánkfalvi; L Kopper
Journal:  Histochemistry       Date:  1990

5.  Identification and synthesis of a recognition signal for the attachment of glycosaminoglycans to proteins.

Authors:  M A Bourdon; T Krusius; S Campbell; N B Schwartz; E Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

6.  Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts.

Authors:  L Kopper; A Bankfalvi; R Mihalik; T T Glant; J Timar
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

7.  Invariant chain trimers are sequestered in the rough endoplasmic reticulum in the absence of association with HLA class II antigens.

Authors:  M S Marks; J S Blum; P Cresswell
Journal:  J Cell Biol       Date:  1990-09       Impact factor: 10.539

8.  Membrane-associated chondroitin sulfate proteoglycans of human lung fibroblasts.

Authors:  G David; V Lories; A Heremans; B Van der Schueren; J J Cassiman; H Van den Berghe
Journal:  J Cell Biol       Date:  1989-03       Impact factor: 10.539

9.  HLA expression in human hepatocellular carcinoma.

Authors:  A C Paterson; R Sciot; M C Kew; F Callea; G M Dusheiko; V J Desmet
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640

10.  Uncoupling of chondroitin sulfate glycosaminoglycan synthesis by brefeldin A.

Authors:  R C Spiro; H H Freeze; D Sampath; J A Garcia
Journal:  J Cell Biol       Date:  1991-12       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.